

Supplement dated and registered 20 June 2022 to the base prospectus approved by the Swedish Financial Supervisory Authority (the “**Swedish FSA**”) on 7 December 2021.



# Nordax Bank

This supplement (Swedish FSA ref. no. 22-16447) (the “**Supplement**”) is a supplement to, and shall be read together with, Nordax Bank AB (publ)’s (the “**Company**”) base prospectus dated 7 December 2021 (SFSA ref. no.21-28155) and the pertaining supplementary prospectus dated 1 March 2022 (SFSA ref. no. 22-5339) (the “**Prospectus**”) and constitutes a supplement pursuant to Article 23 of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”). This Supplement was approved and registered by the Swedish FSA on 20 June 2022. Terms defined in the Prospectus shall have the same meaning when used in this Supplement. In case of conflict between this Supplement and the Prospectus or documents incorporated by reference into the Prospectus, this Supplement shall prevail. The supplement was made public on 20 June 2022 and is available on the Company’s website, [www.nordaxgroup.se](http://www.nordaxgroup.se) (other than the documents incorporated by reference, no information on such website is part of this Supplement or the Prospectus).

This Supplement has been prepared due to: (i) the publication of the Company’s annual report for 2021, which was published on the Company’s website on 28 April 2022, and (ii) the publication of the Company’s interim report for the first quarter of 2022, which was published on the Company’s website on 25 May 2022.

At the time of publication of this Supplement, there are no outstanding offers to purchase or subscribe for transferable securities under the Base Prospectus and thus there is no right of revocation.

### Amendments and supplements to the Prospectus

On page 53, in the table titled “*Incorporation by reference*”, new rows shall be added with the following information:

<b>The Issuer’s annual report for 2021</b> <a href="https://mb.cision.com/Main/7708/3555631/1570925.pdf">https://mb.cision.com/Main/7708/3555631/1570925.pdf</a>	as regards the audited consolidated financial information on page 35 for income statement, page 37 for balance sheet, page 38 for cash flow statement, page 40 for changes in equity capital, pages 42-88 for notes and pages 92-95 for the audit report.
<b>The Issuer’s interim report for the first quarter of 2022</b> <a href="https://mb.cision.com/Main/7708/3573820/1584236.pdf">https://mb.cision.com/Main/7708/3573820/1584236.pdf</a>	as regards the consolidated financial information on page 6 for income statement, page 8 for balance sheet, page 9 for cash flow statement, page 10 for changes in equity capital and pages 12-30 for notes.

On page 54, the text under the heading “*Significant change*” shall be replaced with the following:

“There has been no significant change in the financial position of the Group since 31 March 2022, being the end of the last financial period for which financial information has been published to the date of the Base Prospectus.”